NORWOOD, Mass.–(BUSINESS WIRE)– #DrugDelivery–Veramorph LLC (VeraMorph) is a specialty pharmaceutical company utilizing its “degradable gel” oral drug delivery platform to develop a pipeline of clinically differentiated orally reformulated drug products. The lead product is the first effective oral formulation of fulvestrant, which is the potential best in class endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer (mBC) patients without ESR1 gene mutations. The potential clinical
